Alprostadil (Caverject/MUSE) Adult Dosing: Complete Guide for Men 30 to 49

Why age 30 to 49 does not create a different dose

The current Caverject, Caverject Impulse, and MUSE labels do not provide a special schedule for men aged 30 to 49 [1][2][3]. Dose selection follows erectile dysfunction etiology, response, tolerability, product presentation, and supervised training. Age alone does not justify starting higher, skipping titration, or copying another person's dose.

That matters because alprostadil acts directly on penile smooth muscle and cavernosal arteries. In a major intracavernosal program, increasing doses produced increasing response during office testing, while the effective dose varied across men with neurogenic, vasculogenic, psychogenic, and mixed causes of ED [4]. The same study documented prolonged erection, priapism, pain, bruising, and fibrotic complications, which is why an online dose chart cannot replace observed titration.

The target is not the strongest possible erection. Both Caverject and Caverject Impulse direct the clinician to find the lowest effective dose that produces an erection suitable for intercourse and lasting no longer than one hour [1][2]. The patient remains in the office until the erection has fully subsided during titration.

Caverject vial dosing: the labeled titration sequence

Caverject vials are single-dose presentations containing 20 mcg or 40 mcg deliverable alprostadil after proper reconstitution [1]. Those package strengths are not automatic administered doses. The clinician draws the titrated amount from the reconstituted vial and discards the vial after one use.

For vasculogenic, psychogenic, or mixed ED, the label begins with 2.5 mcg intracavernosally. If the response is partial, another 2.5 mcg may be given during supervised titration within one hour using a new vial. If further titration is needed, later doses rise in 5 to 10 mcg increments at least 24 hours apart [1]. No more than two doses are given within 24 hours during the initial titration process.

For pure neurogenic ED, with spinal cord injury given as the label's example, the starting dose is 1.25 mcg. A second 1.25 mcg dose may be administered within one hour if the first response is partial. If more titration is needed, the label's next step is 5 mcg at least 24 hours later [1]. Post-prostatectomy ED should not automatically be relabeled "pure neurogenic" by a webpage; the treating clinician determines the etiology and protocol.

The Caverject label says doses greater than 60 mcg are not recommended [1]. That corrects the common but inaccurate claim that 40 mcg is the universal maximum simply because 40 mcg is the largest vial strength. A package size, a delivered dose, and a labeled dose ceiling are different concepts.

Caverject Impulse dosing and device limits

Caverject Impulse is a dual-chamber, single-dose syringe system with medication and diluent in one device. It is marketed in 10 mcg and 20 mcg strengths. The 10 mcg system can be set to deliver 2.5, 5, 7.5, or 10 mcg; the 20 mcg system can deliver 5, 10, 15, or 20 mcg [2].

Its etiology-based titration instructions match the vial label: 2.5 mcg for vasculogenic, psychogenic, or mixed ED, and 1.25 mcg for pure neurogenic ED [2]. However, the available device increments matter. The prescriber must choose a presentation capable of delivering the intended dose and train the patient on that exact device. A patient should never improvise a dose that the syringe cannot display.

The Impulse label also states that doses greater than 60 mcg are not recommended, but each marketed Impulse system delivers no more than 20 mcg [2]. This is another reason not to interpret the label ceiling as a routine target or to combine multiple systems without explicit clinical direction.

Home injection frequency and dose changes

After the office establishes a home dose, Caverject and Caverject Impulse are used no more than three times per week, with at least 24 hours between injections [1][2]. The FDA labeling tells patients not to change the home dose without consulting the prescriber. If the response becomes too strong, too weak, painful, unusually prolonged, or inconsistent, the next step is clinical reassessment, not unsupervised escalation.

Each vial or Impulse syringe is single use. The injection site and side of the penis should alternate. The label directs injection along the dorsolateral aspect of the proximal third of the penis, avoiding visible veins, followed by compression with an alcohol swab or sterile gauze for five minutes [1][2]. Patients taking anticoagulants such as warfarin or heparin may have more injection-site bleeding and should follow the prescriber's technique and compression instructions.

The evidence supports efficacy after proper titration, but it also reinforces why training matters. In the six-month self-injection portion of the Linet and Ogrinc program, men reported being able to have sexual activity after 94% of injections, and sexual activity was rated satisfactory after 87% of injections [4]. Priapism occurred in 1% of men, prolonged erections in 5%, fibrotic complications in 2%, and hematoma or ecchymosis in 8%. Those results came from structured studies, not from self-selected online dosing.

MUSE dosing: current strengths and supervised start

MUSE is a transurethral alprostadil system, not an injection. The current May 2024 label lists three marketed strengths: 250 mcg, 500 mcg, and 1000 mcg [3]. Older MUSE studies included a 125 mcg dose, but that historical trial dose should not be presented as a current marketed strength.

The current MUSE prescribing information recommends 250 mcg for initial dosing [3]. Titration occurs under physician supervision to test responsiveness, teach administration, and monitor for hypotension. The dose may be increased or decreased on separate occasions until the lowest dose sufficient for intercourse is found.

At home, MUSE is used as needed, with no more than two administrations in 24 hours. Each applicator contains one dose and is discarded after use [3]. The label says onset is generally within 5 to 10 minutes and duration is approximately 30 to 60 minutes, with individual variation.

The key double-blind MUSE study enrolled 1,511 men for clinic titration. Of those, 996 achieved an erection sufficient for intercourse and moved to randomized home treatment. Among men assigned active MUSE after successful clinic titration, 64.9% reported successful intercourse at least once, compared with 18.6% assigned placebo [5]. These are responder-enriched results and should not be translated into a guarantee for every patient.

Injection and urethral doses cannot be converted

A 250 mcg MUSE system is not "stronger" than a 20 mcg injection merely because its number is larger. Intracavernosal and transurethral delivery have different absorption and exposure. There is no patient-safe microgram-for-microgram conversion between Caverject and MUSE.

A small comparative study of 103 patients found higher response rates with intracavernosal alprostadil than transurethral MUSE, while the adverse-effect patterns differed by route [6]. That study can inform a treatment discussion, but it does not create a conversion formula or establish which route is right for an individual.

Changing from MUSE to Caverject, changing injection presentations, or returning after a long treatment interruption can require new instruction or titration. Follow the current prescriber's plan for the exact product rather than transferring a dose from another formulation.

Conditions that change the safety decision, not a web dose table

The labels do not publish separate renal, hepatic, diabetes, SSRI, or age 30 to 49 dose tables for ED [1][2][3]. Response-based titration still applies, but several conditions can change whether treatment is appropriate or how closely it is supervised.

Caverject and Caverject Impulse are contraindicated in men with conditions that predispose to priapism, including sickle cell anemia or trait, multiple myeloma, or leukemia. They are also contraindicated for ED treatment in men with fibrotic penile conditions and in men with penile implants [1][2]. MUSE has its own contraindications, including certain urethral or penile abnormalities and conditions associated with priapism [3].

Sexual activity itself may be inadvisable for some people with cardiovascular disease. The labels direct clinicians to assess underlying cardiovascular status before ED treatment [1][2][3]. Caverject may cause hypotension, particularly when cavernosal venous leakage raises peripheral alprostadil exposure. MUSE can also cause symptomatic hypotension or syncope, which is one reason the first dose is supervised.

These factors do not justify guessing a lower dose at home. They justify a prescriber reviewing the diagnosis, contraindications, other medications, bleeding risk, anatomy, and cardiovascular fitness before selecting a product and titration plan.

Combination injections and compounded bimix or trimix

Do not add papaverine, phentolamine, or another injected drug to Caverject on your own. The Caverject label states that the safety and efficacy of combinations with other intracavernosal vasoactive medications have not been systematically studied and that such combinations are not recommended [1]. Caverject Impulse carries the same warning [2].

Some clinicians prescribe patient-specific compounded bimix or trimix, but those fixed combinations are not FDA-approved. FDA explains that it does not review compounded drugs before marketing for safety, effectiveness, or quality [7]. A compounded prescription may also use a different concentration than a prior vial, so a volume copied from an old prescription can deliver a different dose.

If single-agent alprostadil is ineffective or poorly tolerated, the decision is a new prescribing decision. It may involve another FDA-approved ED option, a device, a different route, or a patient-specific compound. The AUA guideline emphasizes shared decision-making and informing patients about non-contraindicated options rather than enforcing one universal sequence [8].

Technique, storage, and follow-up

The first injection and titration must be performed by medically trained personnel in the health care provider's office. Before home use, the patient must demonstrate correct preparation and injection technique [1][2]. Needles should never be reused or shared. A bent needle should be discarded rather than straightened.

Storage differs by presentation. Unmixed Caverject Impulse is kept at controlled room temperature; after mixing, it must be used within 24 hours and kept between 2°C and 25°C without freezing [2]. Caverject 20 mcg vials are stored at controlled room temperature. Caverject 40 mcg vials are refrigerated until dispensed, after which label-specific room-temperature allowances apply. Reconstituted Caverject vial solution is used within 24 hours at or below 25°C and is not refrigerated or frozen [1]. MUSE is refrigerated unopened but may be kept at controlled room temperature for up to 14 days [3].

The Caverject labels call for reassessment about every three months or as clinically appropriate [1][2]. Follow-up checks response, dose, technique, bruising, pain, curvature, plaques, or other signs of fibrosis. A four-year prospective study of intracavernosal alprostadil alfadex found sustained effectiveness among continuing participants, but also documented pain, hematomas, prolonged erections, and fibrotic changes over time [9]. Long-term success therefore depends on surveillance, not merely finding an initial dose.

When to call the prescriber or seek emergency care

Seek immediate medical care for an erection lasting more than four hours. Waiting for it to resolve can cause penile tissue damage and permanent loss of erectile function [1][2][3].

Contact the prescriber promptly for a dose that repeatedly lasts longer than intended, new or worsening curvature, a palpable nodule or plaque, severe penile or urethral pain, significant bleeding, fainting, or an inadequate response despite correct use. Stop and clarify instructions if the package, strength, concentration, device, or prescribed volume differs from the prior fill.